Emcure Pharmaceuticals delivered a robust performance for the financial year 2026, crossing the $1 billion revenue milestone with 16.6% growth. The company reported a significant 41% increase in adjusted annual profit and a strong 36% jump in quarterly profit. Key business drivers included international expansion and strategic acquisitions, while the board recommended a final dividend of ₹3.60 per equity share for the year.
Financial Highlights
For the full financial year ended March 31, 2026, Emcure Pharmaceuticals achieved a consolidated revenue from operations of ₹9,204 crore, representing a 16.6% year-on-year growth. The company’s EBITDA rose to ₹1,789 crore, marking a 21.8% increase, while the reported profit after tax reached ₹941 crore, up 33.1% compared to the previous year. For the fourth quarter specifically, the company generated ₹2,470 crore in revenue, reflecting a 16.7% growth, and a reported profit after tax of ₹244 crore.
Strategic Growth and Operations
The company’s growth was driven by a balanced portfolio performance. The domestic business recorded a 10% annual growth, reaching ₹4,027 crore, supported by core therapeutic areas including cardiac, oncology, and central nervous system treatments. Meanwhile, the international business saw a robust 22.2% annual increase, contributing ₹5,177 crore to the total revenue. Strategic initiatives, including in-licensing and the Zuventus minority buyout, have bolstered the company’s leadership position.
Dividend and Leadership Appointments
In addition to the financial results, the Board of Directors has recommended a final dividend of ₹3.60 per equity share of ₹10 each. The board also approved key leadership changes, including the re-appointment of Dr. Mukund Gurjar as a Whole-time Director for one year starting August 28, 2026, and the re-appointment of Mr. Satish Mehta as the Managing Director for a five-year term commencing April 1, 2027. Both appointments are subject to shareholder approval.
Source: BSE
